OncoPharm cover image

Lirafugratinib + LITESPARK011

OncoPharm

00:00

Combination Therapy Has Greater Treatment Toxicity

John Bazar explains that more patients discontinued lenvatinib or belzutifan for toxicity and describes cardiac failure and left-ventricular-function safety signals.

Play episode from 11:41
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app